A Critical Evaluation of Preclinical Testing in China: A Case Study Dr. Diana Galer, Vice President, Strategic Management Group, Pfizer, Inc.		Developing a Global Strategy to Further Innovation Ross Horsburgh, Regional Medical Director, Asia Pacific & Head CRR-APAC, AstraZeneca
	Assessing Which Regions are Most Attractive and Why: A Perspective Balu Balasubramanian, Ph.D., Executive Director, Research and Development, Bristol-Myers Squibb Co.		Data Acceptability and Requirements in China: A Risk/Benefit Analysis Dr. Lee Jia, Project Officer, Toxicology and Pharmacology Branch, DTP, National Cancer Institute/NIH
	Quality vs. Speed: A Regulatory Perspective on the Future Direction of Chinese SFDA and Role of China in Global Drug Development Zili Li, M.D., M.P.H., Director of Clinical Research Operations- Asia Pacific/Head of China Regulatory Policy, Merck		Translational Medicine and Biomarker Development Collaborations in China Jingsong Wang, Ph.D., Director, Clinical Discovery, Bristol-Myers Squibb
	Outsourcing Lead Generation Activities in China, India, and Russia Deborah S. Hartman, Ph.D., Vice President, Lead Generation, AstraZeneca		How to Best Manage R&D Operations in China to Maximize Productivity Samantha Ying Du, Ph.D., CEO, Hutchison MediPharma Ltd.

Planning a Global Strategy Around Intellectual Property Law: IP Barriers, and Trends

Partnering for Medicinal Chemistry, Pharmacology, Animal Models, and GLP Tox
Beyond chemistry and biology outsourcing, what can be done outside of the US and Europe and what are the true possibilities, costs, constraints and efficiencies?

Intellectual Property • Partnering and Collaborations • Regulatory Landscape and Drug Registration • Deals, Licensing, and Risk-sharing • Accessing, Keeping and Managing Talent • International Project and Team Management • Discovery Chemistry • Discovery Biology • Pre-clinical Safety • Investigational Product Supply • Translational Medicine